Osmozis S.A.

As of August 31, 2023, Osmozis S.A. has 2.71M shares outstanding.

As of August 31, 2023, Osmozis S.A. trades at a trailing price-to-earnings ratio of 37.00. The price-to-sales ratio is 2.04, and the price-to-book ratio stands at 5.22.

As of August 31, 2023, Osmozis S.A. trades at an EV/EBITDA multiple of 22.72 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Osmozis S.A. trades at an EV/FCF ratio of 3.28, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of August 31, 2023, Osmozis S.A. maintains a current ratio of 2.62, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 90.00, indicating elevated leverage, while an interest coverage ratio of 3.55 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended August 31, 2023, Osmozis S.A. posted a return on equity (ROE) of 15.33, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.31, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.33, useful for judging operating efficiency across full business cycles.

These figures cover the twelve months ended August 31, 2023. That works out to an effective tax rate of 12.69, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on July 24, 2024, Osmozis S.A.'s stock has gained approximately 44.93% over the past 52 weeks. The 50-day moving average sits at 14.25, while the 200-day moving average is 11.61.

Over the twelve months ended August 31, 2023, Osmozis S.A. posted a gross margin of 116.59, reflecting its pricing power and cost economics. The operating margin of 10.20 and net profit margin of 5.53 provide insight into operational efficiency.

These figures cover the twelve months ended August 31, 2023. Free cash flow yield stands at 28.72, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -22.99, meaning Osmozis S.A. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of August 31, 2023, Osmozis S.A. has an Altman Z-Score of 1.91, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.